Non-inflammatory Lesions Research Articles

Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.

Although truncal acne is thought to have the same pathophysiology as facial acne, treatment response may differ based on body area involvement. Traditionally, prescribers have relied on oral therapies for the management of truncal acne, possibly because oral therapy has been considered more convenient than topical application of medication to the chest and back. A lotion formulation may be particularly well-suited for the treatment of truncal acne. Tazarotene lotion, 0.045% is FDA approved for treatment of acne vulgaris in individuals 9 years of age or older. This pilot study was designed to investigate the efficacy and safety of Arazlo lotion for the treatment of truncal acne. A total of 19 subjects ranging in age from 12 to 58 years completed the 12-week study. There were significant reductions in truncal IGA (the primary endpoint) at each of the study follow-up visits. At week 12, 89% of subjects were clear or almost clear, as assessed by truncal IGA score. There were statistically significant reductions in inflammatory, non-inflammatory, and total lesion counts from baseline to week 12. Treatment with tazarotene lotion 0.045% was well-tolerated, with erythema, dryness, peeling, oiliness, pruritis, and burning generally rated as trace or mild. Most subjects (64% or more) rated the lotion as “Good” or “Excellent” in general and in comparison to their prior medications. Tazarotene lotion, 0.045% is shown to be effective and well-tolerated for the management of truncal acne in this pilot study. Further studies with placebo control and larger populations are warranted. J Drugs Dermatol. 2022;21(7):713-716. doi:10.36849/JDD.6967.

The Role of Herbal Medicine in the Treatment of Acne Vulgaris: A Systematic Review of Clinical Trials.

Over the past few decades, interest in medicinal plants and phytochemicals for the treatment of skin disorders, including acne vulgaris, has progressively increased. Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit, which mainly occurs in adolescents and young adults. The treatment focuses on the four main factors involved in its pathogenesis: increased sebum production, hyperkeratinization, overgrowth of Cutibacterium acnes, and inflammation. The treatment includes topical retinoids, benzoyl peroxide, antibiotics, and oral isotretinoin. In this regard, the use of herbal medicine as a complementary and alternative medicine is a promising strategy. The main objective of this study was to systematically evaluate the efficacy and safety of medicinal plants and phytochemicals in the treatment of acne vulgaris. Three scientific databases (PubMed, Web of Science, and Scopus) were searched from inception to January 2021. Clinical trials comparing herbal therapies with placebo or other medicines for the treatment of acne vulgaris were included and analyzed. Outcome measures of interest comprised acne lesions (inflammatory and noninflammatory), sebum production, acne severity, and quality of life. The risk of bias in the included randomized controlled trials (RCTs) was assessed using the Cochrane risk-of-bias tool. A total of 34 clinical trials involving 1753 participants met the inclusion criteria for this systematic review. Most trials showed that herbal medicine significantly reduces inflammatory and noninflammatory acne lesions and has a relevant effect on acne severity. Some medicinal plants revealed equal or higher efficacy to standard treatments. No significant difference between groups in sebum production and quality of life was observed and no severe adverse events were reported. This systematic review provides evidence that medicinal plants and phytochemicals are promising treatments for mild to moderate acne vulgaris. However, more quality of evidence and standardized methodologies are needed to support their effectiveness and safety claims.

Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients

Background Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Methods Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m2 (underweight-to-normal), 25-<30kg/m2 (overweight), and ≥30kg/m2 (obese). Results Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20–25% were overweight and 15–20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: −63.2%, obese: −56.0%); tretinoin (−57.6%, −53.1%); tazarotene (−59.9%, −56.8%). Mean changes in noninflammatory lesions were: CP/BPO (−54.2%, −50.8%); tretinoin (−51.6%, −44.9%); tazarotene (−56.7%, −54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups. Conclusions CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation.

Clindamycin phosphate, tretinoin with benzoyl peroxide versus clindamycin phosphate and tretinoin combination without benzoyl peroxide for the treatment of acne vulgaris

Introduction: Acne vulgaris (AV) is a prevalent skin disorder among adolescents. Affects around 80–90% of adolescents in the Western population. The present study aimed to compare the therapeutic efficacy of Clindamycin phosphate (CLM), Tretinoin (TN) with Benzoyl peroxide (BP) versus clindamycin phosphate and tretinoin combination without Benzoyl peroxide for treatment of AV. Methodology: 250 patients with mild to moderate acne on the face were enrolled in the study and were divided into two groups; group I (n=125); apply CLM 1.2%, TN 0.025%gel with BP 3.75% gel and group II (n=125) apply only CLM 1.2% and TN 0.025% gel without BP 3.75% gel; once daily at night for 4 weeks. The change in acne lesions was recorded every 2 weekly follow-ups using the global acne grading system and non-inflammatory (NI-L), Inflammatory (I-L) lesions count and Investigator's Static Global Assessment grading. Results: The research involved 250 patients split into two groups: 125 patients in group I and 125 patients in group II. After 4 weeks, the group I had a higher mean percent decrease in non-inflammatory, inflammatory, and total lesion count than group II.

Comparison of topical agents versus invasive agents in facial acne

The purpose of this present research was to compare the application of topical agent and invasive agent for treatment of facial acne. A total of 124 patients with mild to moderate acne entered this prospective, single-blind study comparing topical (benzoyl peroxide 5%) with invasive treatment (microneedling). There were 60 female and 64 male subjects in the present research. Reductions in the mean number of inflamed and non-inflamed lesions were compared using Student's t-test, as were the mean grades for skin tolerability. The incidence of self reported adverse effects were compared using the x' test. A significant difference was noted in baseline assessment of facial erythema between the two groups (P&lt;0.05), being greater in the microneedling group. Comparisons between the two groups showed that microneedling was significantly better than at one month (P&lt;0.05), however benzoyl peroxide 5% was better at two months (P&lt; 0.001), and three months (P&lt;0.001). Microneedling was effective in removing the comedones with immediate effectiveness but the effects were not long lasting with possibility of scar formation when compared to benzoyl peroxide, who didn’t have relapses in the treatment and were cost effective as well.

Diagnostic approach to tinea capitis with kerion: A retrospective study.

Kerion is an inflammatory type of tinea capitis manifesting as boggy crusted nodules. Diagnosis of kerion is often challenging due to high rates of false-negative mycological samples. A retrospective study among children with kerion, prior to antifungal treatment, was conducted to assess rates of false-negative mycological samples. Specimens for direct microscopy and fungal culture were collected at baseline and after administration of an oral antibiotic course, with or without an oral steroid course. Kerion was categorized as highly inflammatory when a painful, moist scalp nodule with spontaneous purulent discharge or exuberant crust was present, or mildly inflammatory when an erythematous, dry scalp nodule was seen. Twenty-three children (mean age 7.9± 3.0 years) were included in the study. Trichophyton tonsurans was the most common species isolated (69.6%). Highly inflammatory kerions were significantly more likely to be culture negative before treatment than mildly inflammatory kerions (80% vs. 16.7%, p< .01). Non-inflammatory tinea capitis lesions (n= 13) were culture positive in all cases. Following a combined oral antibiotic and steroid course given to most highly inflammatory kerions (n= 11/13), higher rates of positive fungal cultures were found compared to baseline (90.9% vs. 18.2%, p< .01). High rates of negative fungal cultures were found only in highly inflammatory kerion. Sampling a highly inflammatory kerion after a combined oral antibiotic and steroid course improved rates of positive fungal cultures. In addition, sampling of non-inflammatory tinea capitis lesions (when present in addition to the kerion) had the highest culture sensitivity.

Role of Lactium™ in Psychodermatology: The CERTAIN Trial# on Patients with Acne Vulgaris.

Stress plays an important role in the causation and aggravation of psychodermatological conditions such as acne vulgaris. Alpha casein hydrolysate (αs1-casein hydrolysate; Lactium) has been shown to decrease serum cortisol levels, reduce stress-related symptoms, and promote relaxation. “This study aimed to compare the efficacy and safety of Lactium™ plus standard care to those of standard of care alone in reducing stress levels and acne severity in patients with acne vulgaris.” The C.E.R.T.A.I.N trial (Name registered with Clinical Trials Registry-India-No. CTRI/2019/01/017172) is a randomized, controlled, multicenter, open-label, two-arm, investigator-initiated clinical trial. A total of 100 patients with moderate-to-severe acne vulgaris were enrolled and randomly assigned to one of the two groups: Lactium™ plus standard care or standard care alone. Stress levels were assessed using serum cortisol levels, Investigator's Global Assessment (IGA) acne severity scale scores, Perceived Stress Scale (PSS) scores, and the Hamilton Anxiety Rating Scale (HAM-A) scores. The Dermatology Life Quality Index (DLQI) was also used to assess the impact of the skin disease on patients' quality of life. At 12 weeks, stress levels were significantly lower in group A (Nixiyax plus standard of care) than that in group B(only standard care), as measured by the change in serum cortisol levels (4.75 ± 4.46 vs. −0.24 ± 5.22). Furthermore, the mean change in PSS scores (3.09 ± 2.04 vs. 0.90 ± 2.76) and HAM-A scores (5.11 ± 1.94 vs. 1.25 ± 3.13) was significant. Patients in both arms had a significant decrease in total, inflammatory, and noninflammatory acne lesions, as well as a significant improvement in DLQI and IGA scores. In patients with moderate-to-severe acne vulgaris, Lactium™ was found to be both safe and well-tolerated. Lactium™ plus standard care is more effective than standard care alone in reducing acne severity through stress reduction.

Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.

Females aged &ge;25 years may have acne with different etiology, presentation, burden, and treatment response than females 18&ndash;24 years. This post hoc analysis investigated efficacy and safety of tazarotene 0.045% lotion in females &ge;18 years or &ge;25 years of age. In two phase 3 double-blind studies, participants 9 years of age and older with moderate-to-severe acne were randomized (1:1) to once-daily tazarotene 0.045% lotion or vehicle lotion for 12 weeks. Pooled data were analyzed for females aged &ge;18 years (n=744) or &ge;25 years (n=335). Assessments included inflammatory/noninflammatory lesion counts, treatment success (&ge;2-grade reduction from baseline in Evaluator&rsquo;s Global Severity Score and score of 0 [clear] or 1 [almost clear]), Acne-Specific Quality of Life (Acne-QoL) questionnaire, treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability. At week 12, tazarotene-treated females in both age groups had greater reductions from baseline versus vehicle in inflammatory (&ge;18 years: 60.6% vs 53.7% [P&lt;0.01]; &ge;25 years: 60.9% vs 57.3% [P&gt;0.05]) and noninflammatory lesions (59.0% vs 48.4% and 61.1% vs 48.8%; P&lt;0.01, both). Rates of treatment success were greater with tazarotene versus vehicle; this difference was significant for females &ge;18 years. Acne-QoL improvements were similar across age groups and generally greater with tazarotene than vehicle. TEAEs were mostly mild to moderate in severity. No age-related trends for safety or tolerability were observed. Tazarotene 0.045% lotion demonstrated comparable efficacy, improvement in quality of life, and safety in adult females aged &ge;18 or &ge;25 years with moderate-to-severe acne. This cosmetically elegant lotion is a well-studied and important treatment option for all patients, particularly adult females. J Drugs Dermatol. 2022;21(5):587-595. doi:10.36849/JDD.6876.

A review article on Winlevi

&lt;p class="abstract"&gt;Acne is a most common multiform skin condition. Androgen plays a major role in acne pathogenesis in both males and females. The appliance of anti-androgen is potentially effective. However, anti-androgens for topical application are not available in market. Clascoterone (cortexolone 17α propionate), an ester derivative of cortexolone is an androgen receptor inhibitor developed as a topical cream and solution for the treatment of androgen dependent skin disorders, including acne vulgaris. Although the mechanism of action of clascoterone (Winlevi) for topical treatment of acne vulgaris is not known. In 2020 clascoterone 1% has been first approved by United States of America (USA) for the topical therapy of acne vulgaris people aged 12 years or above. Assessment of acne is done based on overall severity of acne based on grades- grade 0, grade 1, grade 2, grade 3, and grade 4 (clear- severe). Both inflammatory on non-inflammatory lesions were counted. Treatment success is achieved when the grade or score is clear or almost clear. Clascoterone cream is well tolerated with no significant clinical safety issues. Clascoterone 1% twice daily treatment have the most effective favourable results with low adverse events. Currently first line treatment targeting aspects of acne includes benzyl peroxide topical or oral antibiotics, topical retinoid. Females with acne is treated with combined oral contraceptives (e. g. norgestimate and norethindrone are approved by FDA for treatment of acne in females) or spironolactone which affects androgens. Androgen receptors are present throughout the skin and found in sebaceous glands, dermal cells, and sebocytes. Androgen inhibiton is an effective way for treatment of acne in females.&lt;/p&gt;

Evaluation of tripartite motif 59 and its diagnostic utility in benign bowel diseases and colorectal cancer.

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in developing countries. Tripartite motif-59 (TRIM59) a member of the TRIM ubiquitin ligase family, is a surface molecule that regulates biological processes such as cell proliferation, apoptosis, and tumorigenesis. Previous studies reported that TRIM59 expression was upregulated in human CRC, however, the expression pattern and role of TRIM59 in benign colorectal lesions remain unclear. Sixty patients diagnosed with CRC and 60 patients with benign lesions (Crohn's disease, ulcerative colitis, adenoma, and familial adenomatous polyposis) were recruited to the present study. TRIM59 gene expression was assessed by real-time quantitative polymerase chain reaction. Expression of TRIM59 protein and p-AKT were determined using, enzyme-linked immunoassay while p53 expression was detected by immunohistochemistry. Antioxidant/oxidant role of glutathione (GSH)/malondialdehyde (MDA) were evaluated by colorimetric methods in all of the studied groups. Our results showed upregulated expressions of TRIM59 gene and protein levels in CRC tissues and benign colonic lesions compared to nontumor tissues. Their levels were higher in inflammatory compared to noninflammatory bowel lesions. There were significant interrelations among TRIM59 gene expression, protein levels, tumor, node, metastasis staging, and the presence of metastasis (p < 0.0001). Receiver-operator characteristic curve analyses showed that at the cutoff point of 2.5 TRIM59 mRNA expression can discriminate between CRC cases and benign bowel group (area under the curve [AUC]: 0.639, sensitivity: 86.7%, specificity: 41.7%), and between CRC and controls (AUC: 0.962, sensitivity: 90%, specificity: 91.7%). TRIM59 could be a potential biomarker in the early detection, diagnosis, and treatment of benign colonic lesions and CRC.

Attention Mechanism Guided Deep Regression Model for Acne Severity Grading

Acne vulgaris is the common form of acne that primarily affects adolescents, characterised by an eruption of inflammatory and/or non-inflammatory skin lesions. Accurate evaluation and severity grading of acne play a significant role in precise treatment for patients. Manual acne examination is typically conducted by dermatologists through visual inspection of the patient skin and counting the number of acne lesions. However, this task costs time and requires excessive effort by dermatologists. This paper presents automated acne counting and severity grading method from facial images. To this end, we develop a multi-scale dilated fully convolutional regressor for density map generation integrated with an attention mechanism. The proposed fully convolutional regressor module adapts UNet with dilated convolution filters to systematically aggregate multi-scale contextual information for density maps generation. We incorporate an attention mechanism represented by prior knowledge of bounding boxes generated by Faster R-CNN into the regressor model. This attention mechanism guides the regressor model on where to look for the acne lesions by locating the most salient features related to the understudied acne lesions, therefore improving its robustness to diverse facial acne lesion distributions in sparse and dense regions. Finally, integrating over the generated density maps yields the count of acne lesions within an image, and subsequently the acne count indicates the level of acne severity. The obtained results demonstrate improved performance compared to the state-of-the-art methods in terms of regression and classification metrics. The developed computer-based diagnosis tool would greatly benefit and support automated acne lesion severity grading, significantly reducing the manual assessment and evaluation workload.

Case report: Syndrome of the disconnection of the callus body in a patient with extensive injury - Mellitus Diabetes and malnutrition - Marchiafava-Bignami disease / Relato de caso: Síndrome da desconexão do corpo calo num doente com lesões extensas - Diabetes Mellitus e má nutrição - doença Marchiafava-Bignami

MFL, 51 years old, female, right-handed, diabetic and previous stroke. Non alcoholic, and report of malnutrition. On neurological examination, he presented tactile anomy, visual agnosia, bucovisual apraxia, left hand agraphia, normal graphia right hand with Alexia, and bilateral crossed optical ataxia. Magnetic resonance imaging (MRI) showed extensive lesion with a swollen aspect in commissural fibers of the corpus callosum, notably in the right body and splenium, and corona radiata with hypersignal in T2 / FLAIR, suggesting demyelinating noninflammatory lesion or subacute vascular lesion.

Topical dapsone in the treatment of acne: a systematic review.

Acne is one of the most common dermatological disorders. Initial therapies for acne include topical retinoids, benzoyl peroxide, and topical clindamycin. However, patients who fail initial therapies may benefit from alternative topicals, including dapsone gel. To analyze the current literature studying the efficacy of topical dapsone in the treatment of acne. PubMed, Embase, and Cochrane Library were systematically searched for clinical trials examining the efficacy of topical dapsone in the treatment of acne. Fourteen studies were included in the analysis. Dapsone monotherapy showed a treatment success rate of 40.1-69.4% for dapsone gel 5% and 29.8-47.0% for dapsone gel 7.5% when used for 12-16 weeks. In all studies, inflammatory lesions decreased by a larger percentage than noninflammatory or total lesions. Dapsone gel was also studied in combination with various other acne treatments, including doxycycline, oral isotretinoin, benzoyl peroxide, and topical retinoids. While mild treatment-related adverse effects, most commonly consisting of skin irritation, occurred in 2.0-75.0% of participants, no major treatment-related adverse effects were reported. Limitations of the study include variable treatment regimens making it difficult to compare results across studies. Additionally, adverse effects and skin irritation were reported differently, and potential selection biases exist in the randomized trials. Dapsone gel offers a safe and promising alternative therapy for patients with difficult to treat acne or those who experience adverse effects to first-line therapies.

Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.

The aim of this study is to review the available data on efficacy and tolerability of tazarotene 0.045% lotion. A literature search of MEDLINE (PubMed) and EMBASE databases was completed in November 2021. Articles that discussed efficacy, tolerability, and pharmacology of tazarotene 0.045% lotion, written in English and published before mid-November 2021, were assessed. In two, 12-week phase III clinical trials, tazarotene 0.045% lotion had higher rates of treatment success (study 1: 25.5% and study 2: 29.6%) than individuals who received the vehicle (study 1: 13.0% and study 2: 17.3%) (both Ps < 0.001). Participants treated with tazarotene 0.045% lotion had greater least squares mean reduction in inflammatory (study 1: 55.5% and study 2: 59.5%) and noninflammatory (study 1: 51.4% and study 2: 60%) acne lesions when compared with vehicle (inflammatory acne lesions, study 1: 45.7% and study 2:49%; noninflammatory acne lesions, study 1: 41.5% and study 2: 41.6%) (P < 0.001 for studies 1 and 2). Tazarotene 0.045% lotion was well tolerated. Retinoids are first-line therapy in the treatment of acne vulgaris. However, many patients experience cutaneous irritation, which can decrease patient adherence and efficacy. Tazarotene 0.045% lotion is the first retinoid to utilize polymeric emulsion technology (PET) to efficiently distribute the medication across the skin, decreasing adverse effects while maintaining efficacy. Tazarotene 0.045% lotion is an effective and well-tolerated retinoid recently approved by the US Food and Drug Administration (FDA) for treating acne vulgaris in individuals 9 years of age and older.

Clinical evaluation of efficacy of intralesional platelet-rich plasma injection versus 1064 nm long-pulsed Neodymium:YAG laser in the treatment of inflammatory acne vulgaris in adolescent and post-adolescent patients: a prospective randomized split-face comparative study

Large numbers of local and systemic therapies are available for acne treatment. Common oral or topical retinoids, antibiotics, or keratolytics are used but sometimes are inconvenient, and side effects caused by these conventional therapies prompted a search for effective and safe treatments. This study aimed to evaluate the efficacy of intralesional platelet-rich plasma injection versus 1064 nm long-pulsed Nd:YAG laser in the treatment of moderate inflammatory acne vulgaris in both adolescents and post-adolescent patients. This split-face comparative study was carried out on thirty patients who suffered from moderate inflammatory and non-inflammatory acne vulgaris. The patients were classified into two groups: group I: adolescent (≤ 25 years) and group II: post-adolescent (< 25 years). Each group received four sessions of intralesional PRP injection on one side of the face and a long-pulsed Nd:YAG (1064 nm) laser on the other side with 2 weeks interval. Evaluation was done by blinded dermatologists using photographs and lesions counting and by patient satisfaction. Side effects were also noted. Both groups (adolescents and post-adolescent) showed a high statistically significant improvement of inflammatory as well as non-inflammatory lesions either in PRP or Nd:YAG laser–treated side with no significant difference between the two sides. The intralesional PRP injection and 1064 nm long-pulsed Nd:YAG laser are safe and effective methods for controlling inflammatory as well as non-inflammatory acne vulgaris in both adolescents and post-adolescent patients.

Comparison of red light and blue light therapies for mild-to-moderate acne vulgaris: A randomized controlled clinical study.

Red and blue light therapies are safe and effective treatments for mild-to-moderate acne vulgaris. However, very few previous studies have directly compared the characteristics of these two methods. To compare the efficacy and side effects of red light (RL) and blue light (BL) for acne vulgaris and to assess these two therapies in different types of lesions. A total of 28subjects with mild-to-moderate acne vulgaris were randomized into the RL group or the BL group. Subjects in each group received different light treatments, and they were followed up regularly until 2weeks after the last treatment. The improvement rates of different types of acne lesions were compared between the 2groups, as well as the incidence of adverse reactions. At the 2-week follow-up, the average improvement rate of total acne lesions was 36.2% in the RL group and 30.7% in the BL group (p>.05). The average improvement rate of inflammatory and non-inflammatory lesions was 51.5% and 17.3% in the RL group, compared with 26.4% and 10.0% in the BL group (all p>.05). Treatment-related adverse reactions were observed distinctly in the BL group. Red light and BL therapies have similar efficacy in mild-to-moderate acne vulgaris, especially for inflammatory lesions. RL had advantages with fewer adverse reactions compared with BL.

Comparison of Nadifloxacin's Safety and Effectiveness to Clindamycin at a Tertiary Care Teaching Hospital in the Deccan Plateau

One frequent skin condition is acne vulgaris marked by excessive sebum production and sebaceous gland irritation, which is frequently made worse by Propionibacterium. It has been discovered that antimicrobials such nadifloxacin and clindamycin are useful in treating acne. This study compared the effectiveness of nadifloxacin and clindamycin when taken in individuals with acne vulgaris in terms of the number of inflammatory and non-inflammatory lesions and the overall improvement score. The research cohort was divided into the clindamycin group and the nadifloxacin group at random for this investigation. Clindamycin, benzoyl peroxide, and nadifloxacin were the available local treatments. Patients were directed to cover afflicted regions of acne lesions with a thin coating of medicine at night, such as nadifloxacin gel, clindamycin gel, or benzoyl peroxide gel. By evaluating changes in the total amount of inflammatory and non-inflammatory lesions to use a six - point likert scale to gauge overall improvement at the conclusion of the treatment, the efficacy of the treatment was assessed. In groups of two, the quantity of inflammatory and non-inflammatory lesions reduces with time, with no discernible difference in lesion counts in between the two groups, according to the results. Yet, more patients who used nadifloxacin with benzoyl peroxide than those who used clindamycin with benzoyl peroxide had positive results. In neither group did a patient describe their lesions becoming better or getting better. No apparent difference could be seen in the frequency of unfavourable events between the two treatment groups during the research, and only two adverse events—a burning feeling and dryness—were noted. Finally, it was discovered that the novel fluoroquinolone topical nadifloxacin was safe, efficient, and able to treat mild to moderate face acne. When used with benzoyl peroxide, it had a clinical efficacy that was comparable to clindamycin.

Topical application of bacteriocins from Bacillus subtilis promotes Staphylococcus aureus decolonization in acneic skin and improves the clinical appearance of mild-to-moderate acne.

Patients with mild-to-moderate acne are frequently colonized by Staphylococcus aureus on their skin, which alters microenvironmental skin conditions and exacerbates disease symptoms. Bacteriocins produced by Bacillus subtilis may act as antimicrobial peptides against Gram-positive bacteria. To investigate whether topical application of bacteriocins from B. subtilis could serve as a potential strategy for promoting S. aureus decolonization from acneic skin. The research product was a cream formulation containing 1% bacteriocins from B. subtilis. First, we conducted a 60-day pilot study on the effect of topically applied bacteriocins from B. subtilis on the absolute abundance of S. aureus in 12 patients with mild-to-moderate acne. Second, we designed an 8-week, uncontrolled, open-label, multicentre clinical study to investigate whether the topical application of bacteriocins from B. subtilis reduces the number of inflammatory and non-inflammatory lesions, as well as Global Acne Grading Scale (GAGS) scores, in 373 patients with mild-to-moderate acne. At the microbiological level, quantitative PCR showed a decrease in the absolute abundance of S. aureus in acne areas after topical application of the research product for 60 days (-38%, p < 0.001). In the clinical study, the number of inflammatory and non-inflammatory lesions was found to decrease at 8 weeks by 59% (p < 0.001) and 58% (p < 0.001), respectively, compared with baseline. A 56% decrease was observed for GAGS scores. Topical bacteriocins from B. subtilis can promote S. aureus decolonization in acneic skin, ultimately improving the clinical appearance of mild-to-moderate acne.

Effect of Thirteen Kinds of Photodynamic Therapeutic Schedule on Inflammatory and Non-Inflammatory Lesions in Acne Patients—A Network Meta-Analysis of Randomized Controlled Trials

Effect of Thirteen Kinds of Photodynamic Therapeutic Schedule on Inflammatory and Non-Inflammatory Lesions in Acne Patients—A Network Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of 30% Supramolecular Salicylic Acid Peeling Combined with Isotretinoin Erythromycin Gel in the Treatment of Moderate-to-Severe Acne Vulgaris: A Comparative Study

Background: Both 30% supramolecular salicylic acid (SA) and isotretinoin erythromycin gel (IEG) have proven efficacy with good safety profiles in the treatment of acne vulgaris. Objectives: This study compared the clinical efficacy and safety of 30% SA peeling and IEG in the treatment of moderate-to-severe acne vulgaris. Methods: Patients with moderate-to-severe acne vulgaris were randomized into 3 groups of 30 persons each, and treated with SA peel, or IEG, or SA combine with IEG (SA + IEG group). Evaluation of acne was done by effective rate and individual lesion counts. And the adverse effects and recurrence were recorded. Results: The SA + IEG group was better in clinical efficacy and treating noninflammatory and inflammatory lesions than that of single treatment group (P 0.05). Conclusion: 30% SA combined with IEG had a significant effect in the treatment of moderate-to-severe acne lesions.